Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets

Pharmacotherapy

Volumn 24, Issue 11, 2004, Pages 1539-1545

  DePestel, Daryl D ^a,b,e   Kazanjian, Powel H ^c   Cinti, Sandro K ^c,d   Kauffman, Carol A ^c,d   Carver, Peggy L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Buffered didanosine tablets; DdI; Didanosine; Gastric pH; HIV

Indexed keywords

CALCIUM CARBONATE; DIDANOSINE; MAGNESIUM HYDROXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISPERSIBLE TABLET; DRUG BIOAVAILABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; STOMACH PH;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BUFFERS; DIDANOSINE; GASTRIC MUCOSA; HIV INFECTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MASTICATION; MIDDLE AGED; PROSPECTIVE STUDIES; TABLETS; TIME FACTORS;

EID: 7044234653     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.16.1539.50959     Document Type: Article

References (22)

1. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs 1999;58:1099-135.
2. Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH. Pharmacokinetic- interaction study of didanosine and ranitidine in patients seropositive for human inmmunodeficiency virus. Antimicrob Agents Chemother 1992;36:2075-9.
3. Bristol-Myers Squibb. Videx (didanosine) package insert. Princeton, NJ; 2001.
4. Bristol-Myers Squibb. Videx EC (didanosine) package insert. Princeton, NJ; 2000.
5. Carver PL, Fleisher D, Ling C, et al. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res 1999;16:718-24.
6. Carver PL, Welage LS, Kauffman CA. The effect of food and gastric pH on the oral bioavailability of itraconazole in HIV+ patients [abstr]. Presented at the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, LA, September 15-18, 1996.
7. Welage LS, Carver PL, Revankar S, et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infec Dis 1995;21:1431-8.
8. Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:169-74.
9. Lake-Bakarr G, Quadros E, Beidas S, et al. Gastric secretory failure in patients with acquired immunodeficiency syndrome. Ann Intern Med 1988;109:502-4.
10. Shaffer RT, LaHatte LJ, Kelly JW, et al. Gastric acid secretion in HIV-1 infection. Gastroenterology 1992;87:1777-80.
11. Shelton MJ, Adams JM, Hewitt RG, et al. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy 1997;17:438-44.
12. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1431-8.
13. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;3:292-7.
14. Knupp CA, Barbhaiya RH. A multi-dose pharmacokinetic interaction study between didanosine (Videx®) and ciprofloxacin (Cipro®) in male subjects seropositive for HIV but asymptomatic. Biopharm Drug Dispos 1997;18:65-77.
15. Mummaneni V, Kaul S, Knupp CA. Single oral dose pharmacokinetic interaction study of didanosine and indinavir sulfate in healthy subjects [abstr]. J Clin Pharmacol 1997;37:865.
16. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13.
17. Knupp CA, Brater C, Relue J, Barbhaiya RH. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912-17.
18. Morse GD, Fischl MA, Shelton MJ, et al. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Antimicrob Agents Chemother 1996;40:767-71.
19. Shyu WC, Knupp CA, Pittman KA, Kunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50:503-7.
20. Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol 1993;33:568-73.
21. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability of didanosine systemic exposure in HIV-infected children. AIDS Res Hum Retroviruses 2000;16:415-21.
22. Shelton MJ, Mei H, Hewitt RG, Defrancesco R. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects. Antimicrob Agents Chemother 2001;45:298-300.